目的:研究重组人促红细胞生成素(recombinant human erythropoietin,r-huEPO)对颅脑创伤患者血清S-100β蛋白和IL-10的影响,评价其临床保护作用。方法:31例患者随机分为对照组与治疗组,其中治疗组于规定时间皮下注射r-huEPO,对照组不予r...目的:研究重组人促红细胞生成素(recombinant human erythropoietin,r-huEPO)对颅脑创伤患者血清S-100β蛋白和IL-10的影响,评价其临床保护作用。方法:31例患者随机分为对照组与治疗组,其中治疗组于规定时间皮下注射r-huEPO,对照组不予r-huEPO处理,其他治疗两组相同。两组均在伤后第1、4、7、10、14天静脉采血,利用ELISA法测定S-100β蛋白和IL-10含量,并与患者临床征象作比较。结果:治疗组患者颅内压及脑水肿较对照组减轻,且GCS评分升高;血清S-100β蛋白含量低于对照组,IL-10含量高于对照组,差异均有统计学意义(P<0.05)。结论:利用r-huEPO进行红细胞动员,可通过各种机制抑制颅脑创伤后继发的病理损害及其过度炎症反应,对颅脑创伤具有神经保护作用。展开更多
Notoginsenoside R-111, a novel hexanordammarane glycoside was isolated from the roots of Panax nototginseng, as a minor constituent. Its structure was determined as 6-O-(beta -D-glucopyranosyl)-3 beta ,6 alpha ,12 bet...Notoginsenoside R-111, a novel hexanordammarane glycoside was isolated from the roots of Panax nototginseng, as a minor constituent. Its structure was determined as 6-O-(beta -D-glucopyranosyl)-3 beta ,6 alpha ,12 beta -trihydroxy-22,23,24,25,26,27-hexanordammaran-20-one(1), by means of spectroscopic methods.展开更多
文摘目的:研究重组人促红细胞生成素(recombinant human erythropoietin,r-huEPO)对颅脑创伤患者血清S-100β蛋白和IL-10的影响,评价其临床保护作用。方法:31例患者随机分为对照组与治疗组,其中治疗组于规定时间皮下注射r-huEPO,对照组不予r-huEPO处理,其他治疗两组相同。两组均在伤后第1、4、7、10、14天静脉采血,利用ELISA法测定S-100β蛋白和IL-10含量,并与患者临床征象作比较。结果:治疗组患者颅内压及脑水肿较对照组减轻,且GCS评分升高;血清S-100β蛋白含量低于对照组,IL-10含量高于对照组,差异均有统计学意义(P<0.05)。结论:利用r-huEPO进行红细胞动员,可通过各种机制抑制颅脑创伤后继发的病理损害及其过度炎症反应,对颅脑创伤具有神经保护作用。
文摘Notoginsenoside R-111, a novel hexanordammarane glycoside was isolated from the roots of Panax nototginseng, as a minor constituent. Its structure was determined as 6-O-(beta -D-glucopyranosyl)-3 beta ,6 alpha ,12 beta -trihydroxy-22,23,24,25,26,27-hexanordammaran-20-one(1), by means of spectroscopic methods.